Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Astrazeneca acquired a biotech startup called Amolyt for $800 million, adding a late-stage drug prospect for parathyroidism to its rare disease portfolio. Bio, a lobbying group for the biopharmaceutical industry, changed its stance and now supports a bill to limit China's role in US biotech. German biotech Tubulis secured €128 million in financing to capitalize on the...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has posted guidance on cybersecurity for medical device companies seeking authorization for new devices. Mass General Brigham is collaborating with the FDA to create a brain-computer interface group to address challenges facing developers of such devices. Moody's predicts that AI will expand medtech portfolios and revenue streams in the next two years....

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. 3M has named William Brown as its new CEO, replacing Michael Roman who has led the company since 2018. Abbott has recalled its HeartMate LVAD communication system due to reported injuries linked to the device malfunctioning. 3M's board has approved a health spinoff, with investors set to receive shares of Solventum. An FDA panel has backed Lumicell's agent for breast...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.BioNTech, known for its partnership with Pfizer in developing the first COVID-19 vaccine in the US market, is expecting a return to revenue growth in 2025 after a sales slump of its COVID vaccine affected its bottom line. The company plans to raise prices on the COVID vaccine to maintain revenue while investing in its oncology pipeline for future gains. Meanwhile,...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has delayed its decision on Eli Lilly's Alzheimer's drug, Donanemab, and will convene a committee to discuss the application. President Biden addressed drug prices in the State of the Union, calling for lower prescription drug prices. Additionally, Beigene's Brukinsa was approved for follicular lymphoma, and Amylyx's ALS drug faced uncertainty after a Phase...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Joe Biden has proposed expanding the Inflation Reduction Act to include an increase in the number of prescription drugs subject to price negotiations from 20 to 50 annually. This proposal comes ahead of his State of the Union address. Novo Nordisk has reported positive Phase I data for their next-generation obesity candidate, showing a 13.1% reduction in...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Several developments in the biopharma industry were reported on March 6. Gilead made a bet on 'trispecifics' in a new cancer drug deal, Alumis secured $259 million for its work on a drug targeting Tyk2, Regenxbio's data showed promise in Duchenne gene therapy, Alnylam and Roche's blood pressure drug performed well in a mid-stage trial, and Sionna raised $182 million...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The biotech industry saw a surge in IPOs at the beginning of 2024, with industry insiders discussing the potential for continued growth. Bayer has postponed its plans to split up its divisions, causing a drop in company shares. Apogee, a biotech company, revealed promising early results for a potential long-lasting eczema drug. Nocion secured $62 million for its...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.UnitedHealth is offering financial assistance to providers affected by a cyberattack on Change Healthcare, but providers say it is not enough to cover the financial strain. CVS and Walgreens will begin selling the abortion pill, mifepristone. Hospital compliance with price transparency requirements is declining due to lenient enforcement. The cyberattack on Change...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.A cyberattack has impacted healthcare providers' operations, Molina has lost a Medicaid contract in Virginia, and Walgreens' Villagemd is exiting Illinois. On a positive note, Cleveland Clinic reported a significant net income. A recent survey shows that three-quarters of health professionals expect widespread adoption of artificial intelligence in healthcare....

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Abingworth has invested in Trodelvy development in a deal with Gilead, where one of the investment firm's startups will work with Gilead to expand the cancer drug's label. Cure Ventures has backed a cell therapy startup called Kenai Therapeutics targeting Parkinson's, with $82 million raised and chaired by Jeff Jonas, a former CEO of Sage Therapeutics. Former...

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.UnitedHealth is facing an antitrust probe by the DOJ regarding potential anticompetitive effects. Despite challenges like high labor costs, UHS, a hospital operator, saw revenue growth in 2023. Veradigm is set to delist after missing a Nasdaq deadline. Nurse leaders report burnout and turnover in their roles. A ransomware attack at an urgent care provider may have...

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Denali, a biotech company, received a $500 million investment after facing setbacks in a clinical trial for an ALS drug. Viking presented data suggesting their obesity drug could rival those from Eli Lilly and Novo Nordisk. Janux's shares tripled after positive results for their cancer immunotherapy drug. Minerva's schizophrenia drug was rejected by the...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Title: Pfizer announces new breakthrough in cancer treatmentPfizer recently announced a new breakthrough in cancer treatment. The new drug has shown promising results in clinical trials, with a higher success rate and fewer side effects than current treatments on the market. This is great news for patients who are battling cancer and gives hope for a more...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The biopharma industry is facing challenges with the rocky launch of Roctavian by Biomarin, as well as the departure of AbbVie CEO Richard Gonzalez. Frontier is making strides in developing a better KRAS drug with support from Galapagos. J&J has received EMA backing for earlier CAR-T use in multiple myeloma, and a NEJM paper explores a remarkable CAR-T result in...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. On February 22, 2024, significant developments in the biopharma industry were reported. Ori Capital raised a new biotech fund to support startups working on innovative drugmaking approaches. The Biden administration pledged $100 million towards women's health research as part of an initiative led by First Lady Jill Biden. Moderna faced challenges in transitioning...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##FDA Approves New Drug for Cancer TreatmentIn a groundbreaking move, the FDA has approved a new drug for the treatment of a rare form of cancer. This drug has shown promising results in clinical trials, with patients experiencing significant improvements in their condition. This approval marks a significant advancement in the field of oncology and provides hope for...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Analysts predict that GLP-1 drugs like Zepbound and Ozempic will be highly profitable, reshaping the pharmaceutical industry by treating obesity. Lilly's sales have soared due to demand for their obesity and diabetes drugs, while Amgen is also finding success in the obesity drug market. The FDA has approved a rival to Lilly's weight loss drug Wegovy, providing...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo has licensed the potential first-in-class antibody candidate to Almirall, granting them exclusive global rights to develop and commercialize the anti-IL-21 monoclonal antibody NN-8828. The FDA's shift towards overall survival in cancer drug development is anticipated to have a significant impact, particularly on small biotechs. Moreover, the FDA recently...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##FDA Approves New Cancer DrugThe FDA has approved a new drug for the treatment of a rare form of cancer. The drug has shown promising results in clinical trials and is expected to provide a new treatment option for patients with this type of cancer.##Biotech Company Reports Positive Phase 3 Trial ResultsA biotech company has announced positive results from a phase...

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. French drugmaker Sanofi has announced positive results from a Phase II trial of its experimental drug frexalimab in relapsing multiple sclerosis (MS). The trial, published in the New England Journal of Medicine, showed that frexalimab significantly slowed disease activity in patients with relapsing MS. The drug targets a protein called CD40L, which is involved...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Biogen is facing additional troubles as the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) have issued subpoenas seeking more information. The DOJ is specifically looking into the company's overseas operations, while the SEC is investigating the launch of Biogen's now-discontinued Alzheimer's disease therapy, Aduhelm.In other news, the...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Today we have some exciting news to share with you.## The biotech industry is gaining momentum in 2024, with emerging companies and their investors adapting to industry changes. Biopharma Dive is offering a trendline that explores this new sense of optimism and provides insights into the challenges and opportunities facing these companies. It covers topics such as...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: New treatment for Alzheimer's diseaseIn a groundbreaking development, researchers have announced a new treatment for Alzheimer's disease. The drug, called ADX-100, has shown promising results in early clinical trials. It works by targeting the underlying causes of the disease, rather than just managing the symptoms. This could be a game-changer for the...

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. AstraZeneca is making a big move in the cell therapy manufacturing field. The company plans to invest $300 million in a new facility in Rockville, Maryland. This investment comes after AstraZeneca has made several deals in the therapeutic field, showing their commitment to advancing medical treatments. In other news, Kyverna, a developer of cell therapies for...